SEOUL, South Korea–(BUSINESS WIRE)– #GENEXINE–Genexine, Inc. (KOSDAQ: 095700), a clinical-stage biotechnology company, today announced new preclinical data for its SOX2-targeting bioPROTAC candidate, GX-BP1, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. GX-BP1 is a first-in-class bioPROTAC drug candidate designed to selectively degrade SOX2, a transcription factor widely recognized as a key driver of tumor progression, cancer stemness, and therapeutic
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
